Apellis Presents First Data on APL-2 in C3 Glomerulopathy at ASN Kidney Week

Ads

You May Also Like

Inovio Pharmaceuticals Doses First Subject in Zika Vaccine Clinical Trial

PLYMOUTH MEETING, Pa., July 26, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today ...

Jounce Therapeutics Reports Third Quarter 2018 Financial Results

- Dose escalation cohorts of JTX-2011 Phase 1/2 ICONIC trial, in combination with ipilimumab ...

Cyclacel Pharmaceuticals to Release Third Quarter 2017 Financial Results

BERKELEY HEIGHTS, N.J., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ...